Title: A highly unusual V1 region of Env in an elite controller of HIV infection

Running Title: An unusual Env V1 region in an HIV elite controller

Authors:
Zachary A. Silver\textsuperscript{a,b}, Gordon M. Dickinson\textsuperscript{c,d}, Michael S. Seaman, Ronald C. Desrosiers\textsuperscript{b,}\#

Affiliations:
a. Medical Scientist Training Program, Miller School of Medicine, University of Miami, Miami, FL, USA.
b. Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL, USA.
c. Infectious Diseases Section, Miami Veterans Affairs Health Care System, University of Miami, Miami, FL, USA.
d. Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA.
e. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.

#Corresponding author. Email: r.desrosiers@med.miami.edu.

Word count for "abstract": 250 (limit is 250).
Word count for "importance": 90 (limit is 150).
Word count for main text: 4611
Abstract: HIV elite controllers represent a remarkable minority of patients who maintain normal CD4+ T-cell counts and low or undetectable viral loads for decades in the absence of anti-retroviral therapy. To examine the possible contribution of virus attenuation to elite control, we obtained a primary HIV-1 isolate from an elite controller who had been infected for 19 years, the last 10 of which were in the absence of anti-retroviral therapy. Full-length sequencing of this isolate revealed a highly unusual V1 domain in Envelope (Env). The V1 domain in this HIV-1 was 49 amino acids, placing it in the top 1% of lengths among the 6,112 Env sequences in the Los Alamos National Laboratory online database. Furthermore, it included two additional N-glycosylation sites and a pair of cysteines suggestive of an extra disulfide loop. Virus with this Env retained good infectivity and replicative capacity; however, analysis of recombinant viruses suggested that other sequences in Env were adapted to accommodate the unusual V1 domain. While the long V1 domain did not confer resistance to neutralization by monoclonal antibodies of the V1/V2-glycan-dependent class, it did confer resistance to neutralization by monoclonal antibodies of the V3-glycan-dependent class. Our findings support results in the literature that suggest a role for long V1 regions in shielding HIV-1 from recognition by V3-directed broadly neutralizing antibodies. In the case of the elite controller described here, it seems likely that selective pressures from the humoral immune system were responsible for driving the highly unusual polymorphisms present in this HIV-1 Envelope.

Importance: Elite controllers have long provided an avenue for researchers to reveal mechanisms underlying control of HIV-1. While the role of host genetic factors in facilitating elite control is well-known, the possibility of infection by attenuated strains of
HIV-1 has been much less studied. Here we describe an unusual viral feature found in an elite controller of HIV-1 infection and demonstrate its role in conferring escape from monoclonal antibodies of the V3-glycan class. Our results suggest that extreme variation may be needed by HIV-1 to escape neutralization by some antibody specificities.
INTRODUCTION

Nearly forty years after its discovery, human immunodeficiency virus (HIV) continues to spread at an alarming rate (1). Although anti-retroviral therapy (ART) dramatically reduces HIV transmission from and morbidity among infected individuals, access and adherence to ART can be challenging. In the absence of treatment, HIV-1 infection progresses to the development of AIDS in >99% of cases (2, 3). Elite controllers are a remarkable minority of patients who maintain normal CD4+ T-cell counts and low or undetectable viral loads in the absence of ART (4). Such patients provide researchers with a unique opportunity to study the mechanisms underlying AIDS progression in individuals chronically infected with HIV (5).

Investigations of elite controllers have primarily focused on elucidating host determinants of elite control (6-10). Less studied, however, is the extent to which rare, highly unusual polymorphisms may contribute to elite control (11-14). Highly unusual, attenuating polymorphisms in the viral genome can arise in the presence of immune pressure as a means to escape that pressure (15, 16). The characterization of HIV epitopes targeted by protective cytotoxic T-cells (CTLs) and escape mutants that attenuate circulating virus has provided insights into regions of the HIV genome that are important for the virus to continuously replicate at high levels (17). In addition, infection by a transmitted/founder virus containing a difficult-to-revert, attenuating polymorphism (such as HIV with an inactivating deletion in its nef gene) may also result in elite control (18, 19). Whether immune-mediated or transmitted by the founder virus, the study of highly unusual, potentially attenuating viral polymorphisms in the context of HIV elite control can
improve our understanding of HIV biology and shed light on viral determinants of AIDS pathogenesis.

In this study, we describe an elite controller (VA40774) from whom we isolated a group M, clade B replication-competent strain of HIV-1. Sequencing of the primary HIV-1 isolate from this patient revealed an elongation of the Envelope (Env) V1 domain that renders it the longest in the Los Alamos National Laboratory (LANL) Sequence Compendium and among the top 1% in the LANL online sequence database. When exchanged into other viral backbones, this V1 domain causes an attenuation of viral infectivity. We show that this long V1 domain is sufficient to either partially or completely escape neutralization by the V3-glycan-targeting broadly neutralizing antibodies (bNAb) 10-1074 and PGT121, but not other classes of bNAb.

METHODS

Patient inclusion. The patient from this study was enrolled in an elite controller cohort at the University of Miami, FL. Scientific studies using specimens from these patients have been approved by the Institutional Review Board at the Bruce W. Carter Department of Veterans Affairs Medical Center at the University of Miami.

Cell culture. Patient and donor peripheral blood mononuclear cells (PBMCs) were cultured at a concentration of 1x10^6 cells/mL in Roswell Park Memorial Institute 1640 medium (RPMI) with 10% heat-inactivated fetal bovine serum (HI-FBS, ThermoFisher Scientific) and 50 U/mL of IL-2 (R10-50U, R&D Systems). HEK293T and TZM-bl cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% HI-FBS (D10). The modified SupT1
cell lines for assessing replicative capacity and tropism were cultured in RPMI with 10% HI-FBS (R10). Each media preparation was supplemented with 100 µg/mL of primocin (Invivogen).

**Viral outgrowth.** A single 30 mL blood draw was obtained from elite controller VA40774 and a healthy, HIV-negative donor. PBMCs were isolated by density gradient centrifugation with lymphocyte separation media (MP Biomedicals) in SepMate tubes (STEMCell Technologies). Cells were subsequently counted using a Beckman Coulter Z1 particle counter. Four million PBMCs from VA40774 were cultured overnight in R10-50U. Twenty-five million HIV-negative donor PBMCs were stimulated with phytohemagglutinin-M (PHA-M, ThermoFisher Scientific) for 24 hours to induce lymphoid cell activation and promote a cellular environment permissive to HIV infection. After PHA-M incubation, both patient and donor PBMCs were centrifuged at 500g for 5 minutes, washed, and co-cultured in R10-50U.

The emergence of a primary HIV isolate was monitored using an antigen-capture kit to assess Gag-p24 levels in the supernatant (Advanced Bioscience Laboratories, Inc.).

**Viral RNA extraction and PCR amplification.** A single 1 mL aliquot of co-culture supernatant containing 40 ng Gag-p24/mL was centrifuged at 16,000g for 2 hours at 4°C to pellet virus. The supernatant was carefully removed and the pellet was resuspended in phosphate buffered saline (PBS) to a final volume of 140 µL. Viral RNA was extracted using the QIAamp Viral RNA mini kit (Qiagen) and immediately used to generate cDNA with the SuperScript IV first-strand synthesis system (Invitrogen) and the UNINEF-7' gene-specific
primer (5'-GCACTCAAGGCAAGCTTTATTGAGGCTT-3'). Reverse transcription was carried out for 1.5 hours at 50°C and cDNA products were stored at −20°C.

The LANL tool “PrimerDesign-M” was used to design a primer set for amplification of near full-length ~9 kb HIV-1 genomes (Forward: 5'-GRGAACCACTGCTTAAGCC-3'; Reverse: 5'-GGTCTAACCAGAGAGACCCAGTACAG-3'). Polymerase chain reaction (PCR) was performed on 1 µL of cDNA using the Phusion Hot-Start II High-Fidelity Master Mix (ThermoFisher Scientific) in a single 50 µL reaction. Cycling conditions for this PCR are 98°C for 3 minutes, followed by 30 cycles of 98°C for 10 seconds, 69°C for 15 seconds, 72°C for 5 minutes, with a final extension at 72°C for 5 minutes.

Near full-length HIV sequencing. PCR products were analyzed on a 0.8% agarose gel at 120 V for 70 minutes. The ~9 kb amplicon was gel-extracted using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel). Ten micrograms of gel-purified product were sent to DNA Link, Inc. for preparation of SMRTbell libraries according to the manufacturer's instructions for 10 kb amplicons. After library preparation, amplicon quality was assessed on a Bioanalyzer and SMRT sequencing was performed on the PacBio RSII.

Sequence analysis. The raw data from the PacBio RSII was kindly analyzed by Eric Hunter's laboratory using their published algorithm (20). The LANL "Gene Cutter" tool was used to parse the nucleotide sequences from the near full-length genome into the HIV-1 open-reading frames (ORFs). An amino acid alignment for each of VA40774’s HIV-1 proteins was generated against the HIV-1 clade B consensus, NL4-3, YU2, and ADA. Each protein sequence was carefully analyzed for rare polymorphisms, insertions, or deletions.
against these four reference strains and the entire 2016 LANL Sequence Compendium of HIV-1 (21).

**Generation of recombinant virus.** A 3,246 bp stretch of DNA spanning VA40774’s HIV-1 rev and env (NL-VA40774) was designed *in silico*, gene synthesized (Genscript), and cloned into NL4-3 using the EcoRI and XhoI restriction sites. The V1 domain of HIV-1 Envelope spans HXB2 amino acid positions 131–156. A set of oligonucleotides corresponding to the HXB2-aligned positions 130–156 of NL4-3, NL-AD8, or NL-VA40774 were gene synthesized (Genscript). Each V1 domain was exchanged into the other two strains to generate all possible combinations of V1 recombinants. The integrity of the plasmids was confirmed by sequencing and restriction analysis.

HEK293T cells (American Type Culture Collection) were seeded in a T75 flask such that their confluency would reach ~60% after 24 hours. The cells were transfected with 5 micrograms of each virus-encoding plasmid using jetPRIME (Polyplus-transfection S.A.) and complete media changes were performed at 24 and 48 hours post-transfection. At 72 hours, virus-containing supernatant was harvested and clarified by two rounds of centrifugation (500g for 5 minutes, 2000g for 10 minutes). The concentration of each virus stock was measured using a Gag-p24 antigen-capture kit (Advanced Bioscience Laboratories, Inc.). All viruses were stored at −80°C prior to experimentation.

**TZM-bl infectivity and neutralization assays.** The infectivity and neutralization assays were performed as previously described (22). Briefly, to measure infectivity, each virus stock was diluted to a concentration of 80 ng Gag-p24/mL and 2-fold serial dilutions were
performed eight times, in triplicate, in a 96-well plate. One hundred microliters of each diluted virus stock was transferred to a 96-well plate containing 10,000 TZM-bl cells per well and stored in a 37°C incubator with 5% CO₂. After 48 hours, viral infectivity per ng Gag-p24 was determined based on luciferase activity using the britelite plus kit (PerkinElmer). The neutralization assay was performed similarly, except that a single concentration of virus was used that resulted in approximately 150,000 relative light units (RLU) after 48 hours. Each monoclonal antibody was tested at a primary concentration of 50 µg/mL and titrated five-fold, seven times. The antibody and virus were incubated together for 1 hour prior to the addition of TZM-bl cells. The panel of antibodies tested in the neutralization assays recognize the CD4 binding site (3BNC117, VRC01, VRC07-523, N6), V1/V2-glycans (PG9, PG16, PGDM1400, CAP256-VRC26.25), V3-glycans (10-1074, PGT121, PGT128), gp120/41 (8ANC195), the membrane proximal external region of gp41 (10E8, 4E10, 2F5), the CD4-induced (CD4i) binding site in gp120 (17b), and V3 (447-52D).

**Co-receptor usage and replicative capacity.** Two modified SupT1 cell lines expressing either CXCR4 or CCR5 were kindly provided by James Hoxie (23). Three million cells (SupT1-CCR5 or SupT1-CXCR4) were infected with 10 ng Gag-p24 of each HIV-1 stock at a density of 5x10⁵ cells/mL. The cells were washed with PBS the following day and a complete media change was performed to remove excess virus from each infection condition. The cell cultures were split 1:3 every other day and supernatants were clarified of cellular debris by centrifugation at 500g for 5 minutes. Samples were stored at –20°C prior to analyzing supernatant concentrations of Gag-p24.
HLA, KIR, and CCR5 genotyping. DNA was extracted from VA40774's PBMCs using the DNeasy Blood and Tissue kit (Qiagen). A qualitative PCR was performed to determine whether ccr5 in VA40774 has the 32 bp deletion associated with elite control (24). Four micrograms of DNA were sent to Histogenetics, LLC for SMRT sequencing of the human leukocyte antigen (HLA) complex and killer cell immunoglobulin-like receptors (KIR).

Data Availability. Sequences for the near full-length VA40774 HIV-1 isolate and each of the nine ORFs are available at Genbank under accession number MK499378.

RESULTS

Study subject. VA40774 is a male individual who began biannual HIV testing on February 2, 1992 following his departure from the military service (Figure 1). He first tested positive for HIV-specific antibodies on August 19, 1997 at the age of 30, approximately four months following the initiation of sexual contact with an HIV-positive male who died from AIDS on September 23, 1997. Twenty days following his diagnosis, VA40774 was started on anti-retroviral therapy consisting of Nelfinavir (750 mg three times per day) and Zidovudine/Lamivudine (300/150 mg twice per day). Although the exact date of infection is unknown, the timing of his exposure and previously negative HIV tests indicate that VA40774 was infected between 17 and 130 days prior to the initiation of therapy. On the day that ART was started the patient had a viral load less than 400 copies of RNA per mL of plasma. In December 1997, three months after the initiation of ART, the patient had 500 copies of viral RNA per mL of plasma. Plasma levels of HIV RNA were undetectable during the following eight years of treatment. The patient discontinued ART in December 2005.
and HIV RNA has not been detected in his plasma in the 11 years that have followed, except for a single viral load measurement of 113 RNA copies per mL of plasma in June 2006. VA40774 remains positive for HIV-specific antibodies by western blot and his partner is periodically checked but remains HIV-negative despite unprotected sex over a 15 year period. To explore the possibility that this case of elite control may have a genetic component, we determined the HLA, KIR, and ccr5 genotypes of VA40774 (Table 1). The patient’s class I HLA alleles consist of A*01, A*30, B*15, B*44, C*02, and C*04. The patient is positive for all KIR alleles except for 2DS2, 2DS3, and 3DS1 and is negative for the ccr5Δ32 allele. VA40774 does not have any alleles that are strongly associated with elite control. However, HLA-B*44 has been shown to result in a modestly lower viral set point and slow CD4 decline in a cohort of individuals acutely infected with HIV-1 (25).

Sequence analysis of VA40774’s HIV-1 isolate. Near full-length PacBio sequencing of the HIV-1 isolated from VA40774 in 2016 resulted in 12,831 reads of insert with a total of 36,704,432 sequenced HIV-1 nucleotides. These sequences were deconvoluted to reveal an essentially homogenous virus population belonging to group M, clade B. Analysis of the HIV-1 genome showed an extremely rare V1 domain in Envelope. Specifically, VA40774’s isolate contains an additional 25 amino acids compared to the HIV-1 clade B consensus V1 domain (Figure 2). At 49 amino acids in length, this V1 domain is the longest of 181 group M HIV-1 sequences in the 2016 LANL Sequence Compendium and among the top 1% of the 6,112 group M Env sequences in the LANL online sequence database. The increased length of the V1 domain confers an additional two N-glycosylation sites and two cysteines. While
the addition of N-glycosylation sites among HIV-1 strains with increasingly long V1 domains is common, the addition of cysteines is less commonly found among HIV-1 and more common in HIV-2 and SIV (26, 27). Van den Kerkhof et al. has reported that only 4.7% of HIV-1 isolates contain extra cysteines in V1, while four extra cysteines are present in only 0.1% of HIV-1 sequences (28). Thus, the Envelope V1 domain in VA40774 is notably unique in both its length and cysteine content. We separately analyzed the remaining eight VA40774 HIV-1 proteins for rare amino acid variants. The results of this analysis revealed a total of 14 amino acid substitutions across VA40774’s HIV-1 that are not found among any of the 181 group M HIV-1 sequences from the 2016 LANL Sequence Compendium. Our analyses indicate that such a frequency of rare mutations is standard fare for an individual HIV-1 isolate in the database. Unusual, difficult-to-revert polymorphisms such as deletions, insertions, or frameshift mutations were not observed in these eight ORFs.

**Infectivity of V1 domain recombinants.** To determine the influence of a long V1 domain on HIV-1 particle infectivity, we generated several V1 domain recombinants on the NL4-3, NL-AD8, and VA40774 Env (NL-VA40774) backbones (Figure 3). Infectivity was determined by exposing 10,000 TZM-bl cells to serial dilutions of each virus stock, incubating for 48 hours, and measuring luciferase activity. NL-AD8 was the most infectious strain tested, followed by NL-VA40774 and NL4-3 (Figure 4A–D). While exchange of the V1 domain from NL4-3 into NL-AD8 had no marked effect on infectivity, exchange of NL-VA40774’s V1 domain into NL-AD8 resulted in a 2 log drop in infectivity. NL4-3 could not tolerate V1 domain exchanges, as seen by the complete abrogation of virus infectivity upon
exchanging the wildtype NL4-3 V1 domain with the V1 domains of either NL-AD8 and NL-VA40774. Exchange of the V1 domain from NL4-3 or NL-AD8 into NL-VA40774 did not alter the overall infectivity of NL-VA40774. Thus, NL-VA40774 could well tolerate the exchange of V1 regions from the other strains but the other strains did not tolerate well the exchange of NL-VA40774’s V1 domain into them. The recombinant virus strains listed from most infectious to least infectious are as follows: NL-AD8(43V1), NL-AD8, NL-VA40774(43V1), NL-VA40774(AD8V1), NL-VA40774, NL4-3, NL-AD8(VAV1), NL4-3(AD8V1), and NL4-3(VAV1).

Replicative capacity and tropism of V1 domain recombinants. Given that modifications to the V1 domain may confer CXCR4 tropism (29-31), we investigated the replicative capacity and tropism of each parental strain and V1 recombinant. NL4-3, NL-AD8, and NL-VA40774 all replicated well (Figure 5A–C). Consistent with the TZM-bl infectivity data, there was no replication of the NL4-3(AD8V1) recombinant. NL-AD8, however, replicated well regardless of whether the V1 domain originated from NL4-3 or NL-VA40774. As expected, the NL4-3 strain replicated only in SupT1 cells expressing CXCR4 (Figure 5A), while the NL-AD8 strain replicated only in the CCR5+ SupT1 cells (Figure 5B). NL-VA40774 and the NL-VA40774 V1 exchange recombinants replicated only in the CCR5-expressing cell line (Figure 5C). Thus, exchange of the V1 domains did not have an effect on the tropism of the parental virus (Figure 5A–C).

Neutralization characteristics of VA40774’s HIV-1 Envelope. Given that antibody responses can drive evolutionary changes within the V1 domain during infection, we
investigated several bNAbs for their ability to neutralize the infectivity of NL-VA40774 (Figure 6). NL-VA40774 was phenotyped in TZM-bl neutralization assays using a panel of bNAbs targeting various epitopes within Envelope. NL-VA40774 demonstrated sensitivity to multiple bNAbs targeting the CD4 binding site (CD4bs), V3-glycans, and membrane proximal external region (MPER) of gp41, but was resistant to all V1/V2-glycan bNAbs. The following antibodies did not neutralize NL-VA40774 (i.e., had IC50s above 50 µg/mL): PG9, PG16, PGDM1400, CAP256-VRC26.25, PGT121, 8ANC195, 10E8, 17b, 447-52D. A list of the antibodies tested and the epitopes they recognize is provided in the materials and methods.

We also sought to determine whether plasma from four elite controllers or serum from ten chronically infected HIV patients could neutralize NL-VA40774. Of the four plasma and ten serum samples tested, only three were capable of neutralizing the infectivity of NL-VA40774 (Figure 7A). One of the individuals who neutralized NL-VA40774 was VA40774, suggesting that this patient has a strain-specific response against his own primary isolate. The other two patients whose serum neutralized the infectivity of NL-VA40774 were chronically infected individuals. None of the elite controller plasma samples neutralized NL-VA40774 significantly above background except for VA40774. Based on its relative resistance to neutralization by both chronically infected individuals and several of the bNAbs tested in our panel, NL-VA40774 is most consistent with a tier 2 virus.

Neutralization capacity of VA40774’s plasma. Given that NL-VA40774 has an extremely long V1 domain, and that it is completely resistant to neutralization by V1/V2-glycan-dependent antibodies, we sought to determine the extent to which plasma from VA40774
has neutralizing activity. We therefore tested the ability of VA40774's plasma to neutralize the infectivity of 25 Env pseudoviruses in TZM-bl neutralization assays (Figure 7B). The first panel included clade B viruses and sensitive tier 1 isolates in addition to the standard reference panel of clade B tier 2/3 viruses (32). The second panel consisted of the global reference panel of 12 isolates, which is predictive of breadth and potency against a more extended number of isolates (33). The plasma from VA40774 was only capable of neutralizing the strain SF162.LS, a tier 1A clade B Envelope that is particularly sensitive to neutralizing antibodies. Thus, the neutralization capacity of VA40774’s plasma demonstrated the usual features of autologous neutralization and limited breadth (34).

**Escape from V1/V2-glycan-dependent antibodies is mediated by removal of the N160 glycan and not by V1 domain extension.** Although NL-VA40774 is resistant to neutralization by all four tested V1/V2-glycan-dependent antibodies, this phenotype may be explained by the N160Y substitution in NL-VA40774 (35). We therefore sought to determine the extent to which neutralization by V1/V2-glycan-dependent antibodies could be restored by i) reverting the N160 glycan, ii) swapping the long V1 of NL-VA40774 for the short V1 of NL-AD8, or iii) both (Figure 8).

Restoration of the N160 glycan rendered NL-VA40774 sensitive to neutralization by three of the four V1/V2-glycan-dependent bNAbs, while exchange of the long V1 domain had no effect on neutralization by this class of antibodies (Figure 8A). The only V1/V2-glycan bNAb that was unable to neutralize NL-VA40774(Y160N) was CAP256-VRC26.25, indicating that this antibody does not depend solely on the N160 glycan for neutralization.
We observed that the length of the V1 domain can modestly affect how the N160 glycan influences the broadly neutralizing antibody response. PG16 and PGDM1400 neutralized NL-VA40774(Y160N) slightly more potently when compared to NL-VA40774(AD8V1,Y160N) (Figure 8A). In addition, we tested the ability of a single CD4bs (3BNC117) and V3-glycan (10-1074) bNAb to neutralize these recombinant viruses (Figure 8B). Reversion of the Y160 back to N160 rendered NL-VA40774 slightly more susceptible to neutralization by 10-1074, but not 3BNC117. In the context of the short V1 domain recombinant NL-VA40774(AD8V1), however, reversion of the N160 caused 10-1074 to neutralize virus slightly less potently. Taken together, these results indicate that V1 domain length has a mild influence on the ability of the N160 glycan to modulate neutralization by certain classes of bNAbs.

A long V1 domain mediates escape from some classes of broadly neutralizing antibodies. Our results demonstrate that a long V1 domain does not serve as a mechanism of escape from V1/V2-glycan-dependent antibodies. We next investigated the extent to which the long V1 domain of VA40774 Env may mediate escape from several other bNAb classes, including CD4bs (3BNC117, VRC01, and N6), V3-glycan (10-1074, PGT121, and PGT128), gp120/41 (8ANC195), MPER (10E8, 4E10, 2F5), CD4i (17b), and V3 (447-52D) antibodies.

Swapping the long V1 domain of NL-VA40774 for the short V1 domain of NL-AD8 can substantially modify antibody IC50 in a class- and antibody-specific manner (Table 2). We observed the greatest fold change in IC50 for the V3-glycan-dependent class of bNAbs (Figure 9). NL-VA40774(AD8V1) exhibited a 10-fold increase in sensitivity to
neutralization by 10\(^{-1074}\) compared to NL-VA40774. Although an IC\(_{50}\) for PGT121 was above the limit of detection (>50 µg/mL) for NL-VA40774, the NL-VA40774(AD8V1) recombinant was potently neutralized by PGT121 with a concentration of approximately 0.1 µg/mL – a change of at least 500-fold. In contrast, there was no difference between the IC\(_{50}\)s of PGT128 when NL-VA40774 had a long or short V1 domain. There was little or no difference in the IC\(_{50}\)s for the classes of bNAb\(_s\) recognizing the CD4bs and MPER. The gp120/41 (8ANC195), CD4i (17b), and V3 (447-52) antibodies did not neutralize NL-VA40774 or NL-VA40774(AD8V1).

DISCUSSION

In the majority of patients, untreated HIV-1 infection progresses to AIDS. Elite controllers are individuals who maintain normal blood cell counts and an undetectable viral load throughout decades of infection. Greater understanding of the mechanisms by which certain individuals control HIV-1 replication may provide insights into viral pathogenesis and inform the design of vaccines, therapeutics, and cure strategies. In this study, we set out to determine some of the virologic correlates of nonprogression by sequencing and functionally analyzing the HIV-1 primary isolate from an elite controller. Our analysis of HIV-1 isolated from VA40774 revealed a viral genome belonging to group M, clade B. This particular isolate had an unusual V1 domain in its Envelope at 49 amino acids in length, thus rendering it 25 amino acids longer than the clade B consensus strain. Moreover, the V1 domain in this isolate contained an additional two N-glycosylation sites and two cysteines relative to HXB2.
Each Envelope spike on the HIV-1 virion is a heterotrimeric complex consisting of three gp120 molecules noncovalently bound to three gp41 molecules (36). The mature spike, in its pre-fusion form, is tightly packed to limit the exposure of potentially antigenic epitopes to host neutralizing antibodies. HIV-1 infection results in the development of an extensive antibody repertoire against the viral surface Envelope glycoprotein gp120. Much of the antibody response in a given individual is mounted against the apex region (V1/V2 domains) of gp120 and such antibodies can result in strain-specific neutralization (37).

These antibody responses, however, ultimately drive the evolution of the HIV-1 Envelope sequence in a manner that will result in the loss of antibody potency as the autologous strain acquires resistance mutations. Broadly neutralizing antibodies, in contrast, target more highly conserved difficult-to-access regions of the Envelope timer (38, 39).

While studies have shown that early sequence variation in V1 promotes escape from strain-specific antibody responses, it has only recently surfaced that sequence variation in V1, particularly increases in V1 length, may counteract neutralization by bNAbs (37, 40).

Three separate studies published between 2016 and 2017 have reported a role for a long V1 domain in conferring escape from antibody neutralization (28, 41, 42). These studies demonstrated that a long V1 region with extra cysteines and additional N-glycan sites can evolve within an infected individual to interfere with neutralization by bNAbs of the V3-glycan class. In our study, we observed that exchange of the long V1 domain with a short V1 domain is sufficient to confer neutralization susceptibility to PGT121 and cause a 10-fold decrease in the IC50 for 10-1074. Our results did not show an effect of V1 length on the ability of PGT128 to neutralize NL-VA40774, suggesting that a long V1 domain influences antibody neutralization in both a class- and antibody-specific manner.
Sequence adaptations in the HIV-1 genome that contribute to evasion from host defense mechanisms often come with a cost to viral fitness. We showed that the long V1 domain in NL-VA40774 contributes to virus evasion from the broadly neutralizing antibody response, but that its extraordinary length attenuates infectivity. When exchanged into other virus strains, the unusually long V1 domain in NL-VA40774 dramatically decreased infectivity relative to the parental virus. Van den Kerkhof et al. previously analyzed related Env sequences from a single patient that varied in V1 length from 27 to 41 amino acids and found a statistically significant inverse correlation with virus replication over a three-fold range (28). Although the V1 domain reported here caused a markedly decreased infectivity of laboratory strains, we were surprised to find that NL-VA40774 was highly infectious and that reversion of the long V1 to a short V1 did not affect the infectivity of NL-VA40774. These results suggest that selective pressure for a long V1 domain drives sequence changes outside of V1 to accommodate such an unusually long V1 domain. While it is clear that compensatory changes are required to facilitate the development of a long V1, it remains to be determined what these specific sequence alterations may be.

The long V1 region described here was almost certainly selected by the specificity of the antibody response. What we do not know is whether that antibody-driven selection occurred in the transmitting donor or in the VA40774 recipient. Unfortunately, sufficient samples were not available to determine whether the long V1 evolved in VA40774 or whether VA40774 may have been originally infected with an HIV-1 strain containing the unusually long V1 region. The usual mode of escape from the V3-carbohydrate class of potent broadly neutralizing antibodies is via mutation of the N332 glycan (43). However,
patient VA40774 retains the N-glycan at position 332, which is preferred when antibodies of the V3-carbohydrate class are not present. We can speculate that antibodies of similar specificity but not dependent on N332 arose in the transmitting donor or in VA40774 to drive the unusual escape route of extreme elongation of V1. If the selection for a long V1 occurred in the transmitting donor, viral replication in VA40774 may not have been sufficient to allow reversion back to a preferred, more normal-sized V1. If the selection for the long V1 occurred in VA40774, the presence of memory B cells may prevent reversion back to a more normal-sized V1 but the level of these antibodies more than a decade later may be too low to detect because there are no longer Env sequences present to drive their expression to detectable levels.

In summary, we describe an elite controller whose HIV-1 isolate has an extremely long V1 domain. Our results demonstrate that a long V1 domain promotes escape from some, but not all, of the V3-glycan bNAbs and that sequence accommodations within Envelope but outside of V1 are necessary to prevent a reduction in viral infectivity. We hope that these findings contribute to the growing literature on escape from broadly neutralizing antibodies and provide insights into the potentially attenuating effects of such escape mutations.

ACKNOWLEDGMENTS

The authors would like to acknowledge W.A. Lauer for assistance with the viral outgrowth assay, J.M. Martinez-Navio for supplying the V3-glycan-dependent broadly neutralizing antibodies, and S.P. Fuchs for critically reading the manuscript. We would also like to thank D.A. Dilernia and E. Hunter for their analysis of VA40774’s HIV-1 isolate and J. Hoxie for
providing the modified SupT1 cells. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers F30AI134381 and R01AI104523. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
REFERENCES

1. UNAIDS. 2018. Fact Sheet - World AIDS Day 2018.
2. Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, Leitman E, Moonsamy A, McGregor C, Hurst J, Groll A, Mori M, Sinmyee S, Thobakgale C, Tudor-Williams G, Prendergast AJ, Kloverpris H, Roider J, Leslie A, Shingadia D, Brits T, Daniels S, Frater J, Willberg CB, Walker BD, Ndung’u T, Jooste P, Moore PL, Morris L, Goulder P. 2016. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med 8:358ra125.
3. Sabin CA, Lundgren JD. 2013. The natural history of HIV infection. Curr Opin HIV AIDS 8:311-7.
4. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. 2012. Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors. AIDS Res Treat 2012:161584.
5. Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O’Connell RJ, O’Doherty U, Chun TW, Connors M, Migueles SA. 2012. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 119:4645-55.
6. Goulder PJ, Watkins DI. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8:619-30.
7. Martin MP, Carrington M. 2013. Immunogenetics of HIV disease. Immunol Rev 254:245-64.
8. Madhavi V, Wines BD, Amin J, Emery S, Lopez E, Kelleher A, Center RJ, Hogarth PM, Chung AW, Kent SJ, Stratov I. 2017. HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. J Virol 91.

9. Shasha D, Karel D, Angiuli O, Greenblatt A, Ghebremichael M, Yu X, Porichis F, Walker BD. 2016. Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors. J Leukoc Biol 100:1425-1433.

10. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-71.

11. Casado C, Pernas M, Sandonis V, Alvaro-Cifuentes T, Olivares I, Fuentes R, Martinez-Prats L, Grau E, Ruiz L, Delgado R, Rodriguez C, del Romero J, Lopez-Galindez C. 2013. Identification of a cluster of HIV-1 controllers infected with low replicating viruses. PLoS One 8:e77663.

12. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 82:8422-30.

13. Kikuchi T, Iwabu Y, Tada T, Kawana-Tachikawa A, Koga M, Hosoya N, Nomura S, Brumme ZL, Jessen H, Pereyra F, Trocha A, Walker BD, Iwamoto A, Tokunaga K,
Miura T. 2015. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. J Virol 89:4992-5001.

14. Chen J, Tibroni N, Sauter D, Galaski J, Miura T, Alter G, Mueller B, Haller C, Walker BD, Kirchhoff F, Brumme ZL, Ueno T, Fackler OT. 2015. Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma. PLoS One 10:e0120434.

15. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA, Toth I, Frahm N, Alter G, Brander C, Carrington M, Walker BD, Altfeld M, Heckerman D, Allen TM. 2009. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol 83:1845-55.

16. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, Oniangue-Ndza C, Martin M, Li B, Khakoo SI, Carrington M, Allen TM, Altfeld M. 2011. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476:96-100.

17. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, Evans DT, Desrosiers RC, Mothe BR, Sidney J, Sette A, Kunstman K, Wolinsky S, Piatak M, Lifson J, Hughes AL, Wilson N, O’Connor DH, Watkins DI. 2004. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 10:275-81.

18. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228-32.

19. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. 1999. Immunologic and
virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340:1715-22.

20. Dillernia DA, Chien JT, Monaco DC, Brown MP, Ende Z, Deymier MJ, Yue L, Paxinos EE, Allen S, Tirado-Ramos A, Hunter E. 2015. Multiplexed highly-accurate DNA sequencing of closely-related HIV-1 variants using continuous long reads from single molecule, real-time sequencing. Nucleic Acids Res 43:e129.

21. Brian Foley TL, Cristian Apetrei, Beatrice Hahn, Ilene Mizrachi, James Mullins, Andrew Rambaut, Steven Wolinsky, and Bette Korber editors. HIV Sequence Compendium 2016. Publisher: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. LA-UR-16-25625.

22. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131-46.

23. Del Prete GQ, Haggarty B, Leslie GJ, Jordan AP, Romano J, Wang N, Wang J, Holmes MC, Montefiori DC, Hoxie JA. 2009. Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. J Virol 83:9911-22.

24. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692-8.
25. Zhang X, Huang X, Xia W, Li W, Zhang T, Wu H, Xu X, Yan H. 2013. HLA-B*44 is associated with a lower viral set point and slow CD4 decline in a cohort of Chinese homosexual men acutely infected with HIV-1. Clin Vaccine Immunol 20:1048-54.

26. Wang WK, Mayer KH, Essex M, Lee TH. 1996. Sequential change of cysteine residues in hypervariable region 1 of glycoprotein 120 in primary HIV type 1 isolates of subtype B. AIDS Res Hum Retroviruses 12:1195-7.

27. Wang WK, Essex M, Lee TH. 1995. Uncommon gp120 cysteine residues found in primary HIV-1 isolates. AIDS Res Hum Retroviruses 11:185-8.

28. van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ. 2016. HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology 13:48.

29. Del Prete GQ, Leslie GJ, Haggarty B, Jordan AP, Romano J, Hoxie JA. 2010. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist. J Virol 84:8777-89.

30. Carrillo A, Ratner L. 1996. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 70:1310-6.

31. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. 1994. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 68:2253-9.
32. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicted neutralizing antibodies. J Virol 79:10108-25.

33. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicted neutralizing antibodies. J Virol 88:2489-507.

34. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144-9.

35. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-43.

36. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410:582-608.
37. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324:572-5.

38. Mouquet H. 2014. Antibody B cell responses in HIV-1 infection. Trends Immunol 35:549-61.

39. Burton DR, Mascola JR. 2015. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16:571-6.

40. Laird ME, Igarashi T, Martin MA, Desrosiers RC. 2008. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 82:11054-65.

41. Deshpande S, Patil S, Kumar R, Hermanus T, Murugavel KG, Srikrishnan AK, Solomon S, Morris L, Bhattacharya J. 2016. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology 13:60.

42. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. 2017. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. J Virol 91.

43. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR. 2014. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6:236ra63.
Figure 1 - Timing of HIV-1 infection in VA40774. VA40774 tested positive for HIV-1 specific antibodies in August 1997 and began treatment with Nelfinavir and Zidovudine/Lamivudine shortly thereafter. At the time of ART initiation, the patient had a viral load <400 RNA copies per mL of plasma. The patient’s viral load reached 500 copies of viral RNA per mL of plasma three months following the initiation of ART but remained negative for the following 8 years of treatment. Seven months after therapy was discontinued, the patient’s viral load reached 113 copies of viral RNA per mL of plasma. Since this time, the viral load has remained under the limit of detection (<50 copies of viral RNA per mL of plasma). The patient’s CD4+ T-cell counts have remained above 600 cells per µL of blood throughout infection.
Figure 2- Comparison of Envelope sequences reveals a dramatic elongation of the V1 domain in an HIV-1 elite controller. T-Coffee alignment of VA40774’s Envelope V1 domain against the HIV-1 clade B consensus, one CXCR4-tropic (NL4-3), and two CCR5-tropic (ADA, YU2) viruses reveals the presence of an elongation in V1. The V1 domain in VA40774’s HIV Envelope contains two cysteines (yellow boxes) separated by 12 amino acids and has two additional sites for N-linked glycosylation (NXT/NXS). Amino acid positions are shaded in gray where an amino acid represents more than 51% of the variation for that position. Positions for which there is no consensus amino acid are left unshaded. Gaps in the amino acid sequence are shown with a dash (-).
Figure 3 - Schematic of recombinant viruses. HIV env sequences of NL4-3, NL-VA40774, and NL-AD8 were gene synthesized and subcloned to generate several recombinant viruses with different Envelopes and V1 domain sequences. Stretches of amino acids belonging to NL4-3, NL-VA40774, and NL-AD8 are depicted in green, orange, and blue, respectively (43V1 = V1 domain of NL4-3; AD8V1 = V1 domain of NL-AD8; VAV1 = V1 domain of NL-VA40774).
Figure 4 - Comparative levels of infectivity. TZM-bl cells were infected with serial dilutions of each V1 domain recombinant and infectivity was determined based on luciferase activity, or relative light units (RLU), after 48 hours.

(A) Exchange of the V1 domain from either NL-AD8 or NL-VA40774 into the NL4-3 background.

(B) Exchange of the V1 domain from either NL4-3 or NL-VA40774 into NL-AD8.

(C) Exchange of the V1 domain from either NL4-3 or NL-AD8 into NL-VA40774.

(D) Compilation of Figures 4A–C.
Figure 5- Replicative capacity and co-receptor usage of V1 recombinants. A modified SupT1 cell line expressing either CXCR4 (blue) or CCR5 (green) was infected with each V1 recombinant to determine the extent to which the V1 domain may alter replicative capacity and co-receptor usage.

(A) Exchange of the V1 domain from NL-AD8 into NL4-3 was not compatible with virus replication. As expected, NL4-3 only replicated in the SupT1 cell line expressing CXCR4 with peak virus production on day 19.

(B) Exchange of the V1 domain from NL4-3 or NL-VA40774 into NL-AD8 had minimal effect on NL-AD8 replication. The V1 domain recombinants NL-AD8(43V1) and NL-AD8(VAV1) reached peak virus production on day 13, two days earlier than wild-type NL-AD8. The V1 domain exchanges had no effect on the tropism of NL-AD8.

(C) NL-VA40774 is a strictly CCR5-tropic isolate with replication kinetics that are minimally altered by V1 exchanges. The V1 domain recombinants NL-VA40774(43V1) and NL-VA40774(AD8V1) reached peak virus production on day 9, in contrast with the parental NL-VA40774 which peaked on day 11. Exchange of the V1 domains from either NL4-3 or NL-AD8 did not affect the tropism of NL-VA40774.
Figure 6 - Neutralization characteristics of env recombinant. NL-VA40774 demonstrated sensitivity to bNAbs targeting the CD4bs, V3-glycans, and MPER, but interestingly was resistant to all V1/V2-glycan bNAbs. The concentration of bNAb required for 50% neutralization of NL-VA40774 (IC50) is shown in red and IC50 values >50 µg/mL are shown in black. The V3-glycan antibody PGT128 was the most potent inhibitor of NL-VA40774, followed by the CD4bs antibodies: VRC07-523, 3BNC117, and VRC01. Continuing in order of decreasing potency is the V3-glycan antibody 10-1074 followed by the MPER antibodies 2F5 and 4E10. The following antibodies did not neutralize NL-VA40774 (i.e., had IC50s above 50 µg/mL): PG9, PG16, PGDM1400, CAP256-VRC26.25, PGT121, 8ANC195, 10E8, 17b, 447-52D.
Figure 7 - Neutralization characteristics of NL-VA40774 and VA40774 plasma.

(A) Serum from 10 HIV-infected individuals and plasma from 4 HIV elite controllers, including VA40774, were tested for their ability to neutralize NL-VA40774. VA40774 (blue) and two chronically infected individuals (red) could significantly neutralize NL-VA40774, while the remaining twelve patients could not neutralize NL-VA40774 (black). Titers >3-fold above MuLV Control are considered significant.

(B) A single plasma sample from VA40774 was screened for its ability to neutralize two panels of HIV-1 Env pseudoviruses in TZM-bl neutralization assays. VA40774’s plasma exhibited markedly low neutralizing activity. Of the 25 viruses tested, VA40774’s plasma was only capable of neutralizing the tier 1A strain SF162.LS (red). The following viruses were not neutralized by VA40774’s plasma (black): BaL.26, 6535.3, QH0692.42, SC422661.8, AC10.0.29, RHPA4259.7, REJO4541.67, WITO4160.33, TR0.11, THRO4156.18, CAAN5342.A2, PVO.4, TRJO4551.58, 25710-2.43, 398-F1_F6_20, CNE55, Ce1176_A3, X1632_S2_B10, Ce703010217_B6, 246-F3_C10_2, CH119.10, X2278_C2_B6, CNE8, and BJOX002000.03.2.
Figure 8- Role of the N160 glycan in determining the NL-VA40774 neutralization phenotype. NL-VA40774 and three NL-VA40774 recombinants were tested for their sensitivity to antibody neutralization.

(A) Restoration of the N160 glycan rendered NL-VA40774 sensitive to neutralization by three of the four V1/V2-glycan-dependent bNAbs. In the presence of the N160 glycan, PG16 and PGDM1400 had slightly lower IC50s when the long V1 domain of NL-VA40774 was also present. Exchanging NL-VA40774’s long V1 domain with AD8V1 did not render the virus susceptible to neutralization by V1/V2-glycan bNAbs. Similarly, mutating the Y160 to N160 did not change the neutralization resistance of NL-VA40774 to CAP256-VRC26.25.

(B) There was no significant difference in the IC50 of CD4bs bNAb 3BNC117 when NL-VA40774 was modified to contain AD8V1, the N160 glycan, or both. In contrast, the IC50 of V3-glycan bNAb 10-1074 decreased by 1 log when the short V1 domain of NL-AD8 was exchanged into NL-VA40774. The IC50 of 10-1074 was slightly lower in NL-VA40774(Y160N) than in NL-VA40774, but slightly higher in NL-VA40774(AD8V1,Y160N) compared to NL-VA40774(AD8V1).
Figure 9 - V1 domain length serves as an escape mechanism from some V3-glycan broadly neutralizing antibodies. NL-VA40774 (red) and NL-VA40774(AD8V1) (blue) were tested for their capacity to be neutralized by V3-glycan broadly neutralizing antibodies (PGT121, PGT128, 10-1074). Exchanging the long V1 domain of NL-VA40774 with the short V1 domain of NL-AD8 rendered the virus at least 500-fold more susceptible to neutralization by PGT121 and 10-fold more susceptible to 10-1074. Exchange of the long V1 domain with a short V1 domain had no effect on neutralization by PGT128.
| Subject | ccr5Δ32 allele | HLA genotype | KIR genotype |
|---------|----------------|--------------|--------------|
| VA40774 | No             | 01:01:01:01, 30:01:01 | 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 2DP1, 3DP1 |
|         |                | 15:47:01, 44:03:01 | 2DS2, 2DS3, 3DS1 |
|         |                | 02:10, 04:01:01:01 |   |
Table 2 - Fold change in IC50 with a long versus short V1 domain

| Monoclonal Antibody | Epitope       | IC50 (µg/mL) | Fold Change* |
|---------------------|---------------|--------------|--------------|
|                     |               | NL-VA40774   | NL-VA40774(AD8V1) |       |
| 3BNC117             | CD4bs         | 0.048        | 0.031        | 1.548 |
| VRC01               | CD4bs         | 0.470        | 0.410        | 1.146 |
| N6                  | CD4bs         | 0.150        | 0.130        | 1.154 |
| PG9                 | V1/V2-glycan  | >50          | >50          | N.D.  |
| PG16                | V1/V2-glycan  | >50          | >50          | N.D.  |
| PGDM1400            | V1/V2-glycan  | >50          | >50          | N.D.  |
| CAP256-VRC26.25     | V1/V2-glycan  | >50          | >50          | N.D.  |
| 10-1074             | V3-glycan     | 0.567        | 0.053        | 10.698|
| PGT121              | V3-glycan     | >50          | 0.100        | >500  |
| PGT128              | V3-glycan     | >50          | >50          | >500  |
| 8ANC195             | gp120/41      | >50          | >50          | N.D.  |
| 10E8                | MPER          | >50          | >50          | N.D.  |
| 4E10                | MPER          | 29.820       | 33.040       | 0.903 |
| 2F5                 | MPER          | 12.620       | 14.680       | 0.860 |
| 17b                 | CD4i          | >50          | >50          | N.D.  |
| 447-52D             | V3            | >50          | >50          | N.D.  |

*a For several antibodies, the IC50 remained >50 µg/mL whether NL-VA40774 had a long or short V1 domain. In these cases, the fold change is listed as “N.D.” for “no difference.”*